Biote (BTMD) Inventories, Finished Goods : $16.2 Mil (As of Sep. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Biote Inventories, Finished Goods?

Biote's quarterly finished goods increased from Mar. 2024 ($18.9 Mil) to Jun. 2024 ($19.2 Mil) but then declined from Jun. 2024 ($19.2 Mil) to Sep. 2024 ($16.2 Mil).

Biote's annual finished goods increased from Dec. 2021 ($9.6 Mil) to Dec. 2022 ($11.2 Mil) and increased from Dec. 2022 ($11.2 Mil) to Dec. 2023 ($17.3 Mil).

Biote Inventories, Finished Goods Historical Data

The historical data trend for Biote's Inventories, Finished Goods can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biote Inventories, Finished Goods Chart

Biote Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Inventories, Finished Goods

4.32

9.62

11.18

17.31

Biote Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Inventories, Finished Goods	Get a 7-Day Free Trial											11.08	17.31	18.92	19.21	16.20

Biote Inventories, Finished Goods Calculation

The products in a manufacturer's inventory that are completed and are waiting to be sold.

Biote Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » Biote Corp (NAS:BTMD) » Definitions » Inventories, Finished Goods

Comparable Companies

Traded in Other Exchanges

N/A

Address

1875 West Walnut Hill Lane, Suite 100, Irving, TX, USA, 75038

Website

https://www.biote.com

Biote Corp operates a growth practice-building business within the hormone optimization space. It provides the necessary components to enable Biote-certified practitioners to establish, build, and successfully implement a program designed to optimize hormone levels using personalized solutions for their patient populations.

Executives

Mary Elizabeth Conlon	officer: General Counsel	C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Anil K Shrivastava	10 percent owner	200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
Michael David Braner	10 percent owner	200 PARK AVENUE, 17TH FLOOR, NEW YORK NY 10016
Daniel M. Friedberg	10 percent owner	C/O SAGARD CAPITAL, 325 GREENWICH AVENUE, GREENWICH CT 06830
325 Capital Llc	10 percent owner	757 THIRD AVENUE, 20TH FLOOR, NEW YORK NY 10017
Mary Joan Puncochar	officer: Chief Commercial Officer	C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038
Roystone Capital Holdings Llc	10 percent owner	767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Roystone Capital Management Lp	10 percent owner	780 THIRD AVENUE, 41ST FLOOR, NEW YORK NY 10017
Samar Jagat Kamdar	officer: Chief Financial Officer	7042 CORONADO AVE., DALLAS TX 75214
Marc D Beer	director	C/O AEGERION PHARMACEUTICALS, 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960
Guines Llc	10 percent owner	767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Richard R Barrera	10 percent owner	767 THIRD AVENUE, 29TH FLOOR, NEW YORK NY 10017
Debra L Morris	director	11620 WILSHIRE BOULEVARD, SUITE 1000, LOS ANGELES CA 90025
Andrew R Heyer	director, officer: President and Director	501 MADISON AVENUE, FLOOR 5, NEW YORK NY 10019
Teresa Sue Weber	director, officer: Chief Executive Officer	C/O BIOTE CORP., 1875 W. WALNUT HILL LN #100, IRVING TX 75038